Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.43 |
| ▸ | IL1RN | P18510 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6365962 | 0.74 | CA1 (0.49) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL16720110 | 0.72 | CA1 (0.50) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL6305580 | 0.72 | POLB (0.33) | KEAP1MEN1KMT2AALDH1A1PKM | |
| SCHEMBL6916246 | 0.71 | CA1 (0.41) | CYP2C9CA1CA2MMP1MMP2 | |
| SCHEMBL4036900 | 0.70 | ALDH1A1 (0.52) | KEAP1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4254051 | 0.69 | POLB (0.54) | CYP2C9MMP2MEN1KMT2ALMNA | |
| SCHEMBL27127795 | 0.68 | CYP2C9 (0.43) | CYP2C9CA1CA2MMP1MMP2 | |
| SCHEMBL9713098 | 0.67 | CYP3A4 (0.49) | CYP2C9CA1KAT6AMEN1KMT2A | |
| SCHEMBL8639257 | 0.66 | ADRA2A (0.42) | CYP2C9CA1CA2MMP1MMP2 | |
| SCHEMBL8545489 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405455-B1 | 2-OXINDOLE COMPOUNDS | CHEMOCENTRYX INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-10596163-B2 | Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides | CHEMOCENTRYX, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| CN-107266425-B | Pyrazol-1-yl benzene sulfonamides as CCR9 antagonists | 坎莫森特里克斯公司 | 2020-03-03 | — | — | CN | disclosed |
| CN-107266425-B | Pyrazol-1-yl benzene sulfonamides as CCR9 antagonists | 坎莫森特里克斯公司 | 2020-03-03 | — | — | CN | disclosed |
| CN-107266425-B | Pyrazol-1-yl benzene sulfonamides as CCR9 antagonists | 坎莫森特里克斯公司 | 2020-03-03 | — | — | CN | disclosed |
| US-10137120-B2 | Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides | CHEMOCENTRYX, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| CN-107266425-A | Pyrazol-1-yl benzene sulfonamides as CCR9 antagonists | 坎莫森特里克斯公司 | 2017-10-20 | — | — | CN | disclosed |
| CN-104520288-B | Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists | 坎莫森特里克斯公司 | 2017-05-17 | — | — | CN | disclosed |
| CN-104520288-B | Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists | 坎莫森特里克斯公司 | 2017-05-17 | — | — | CN | disclosed |
| CN-104520288-A | Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists | CHEMOCENTRYX | 2015-04-15 | — | — | CN | disclosed |
| CN-1371286-A | Use of cyclooxygenase-2 inhibitor matrix metallappoteinase inhibitor antineoplastic agent and optionally radiation as combination treatment of neoplasia | SEARLE & CO (US) | 2002-09-25 | — | — | CN | disclosed |
| EP-1140183-A1 | USE OF A MATRIX METALLOPROTEINASE INHIBITOR AND AN INTEGRIN ANTAGONIST IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1027048-A2 | SELECTIVE CYCLOOXYGENASE-2 INHIBITORS AGAINST PREMATURE LABOR | G.D. SEARLE & CO. (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-2000038719-A1 | USE OF A MATRIX METALLOPROTEINASE INHIBITOR AND AN INTEGRIN ANTAGONIST IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| CN-1247470-A | Methods of using cyclooxygenase-2 inhibitors as anti-angiogenic agents | SEARLE & CO (US) | 2000-03-15 | — | — | CN | disclosed |
| CN-1244122-A | Methods of treating and preventing neoplasia using cyclooxygenase-2 inhibitors | SEARLE & CO (US) | 2000-02-09 | — | — | CN | disclosed |
| US-5972986-A | USING PHENYLSULFONAMIDE CONTAINING COMPOUND | G.D. SEARLE & CO. (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1999022720-A2 | SELECTIVE CYCLOOXYGENASE-2 INHIBITORS AGAINST PREMATURE LABOR | G.D. SEARLE & CO. (US) | 1999-05-14 | — | — | WO | disclosed |
| US-5886016-A | ANTIINFLAMMATORY AGENT WITH MINIMAL SIDE EFFECTS FOR TREATING ARTHRITIS | G.D. SEARLE & CO. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5516907-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1996-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10596163-B2 | Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides | CCR9, CCR1, CCR3 | CYP2C9 1243/4885CA1 2892/4885CA2 3658/4885 |
| US-10137120-B2 | Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides | CCR9, CCR1, CCR3 | CYP2C9 1243/4885CA1 2892/4885CA2 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.